Cargando…

A Study of Two Cases Co-Infected with SARS-CoV-2 and Human Immunodeficiency Virus

Detalles Bibliográficos
Autores principales:	Zhang, Rong, Chen, Xiaohua, Huang, Yuqing, Zhang, Qi, Cheng, Yan, Zhang, Nan, Zhang, Haibo, Yang, Bo, Liu, Fang, Liu, Yingle, Lan, Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475944/ https://www.ncbi.nlm.nih.gov/pubmed/32894406 http://dx.doi.org/10.1007/s12250-020-00280-9

Ejemplares similares

ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens
por: Suo, Tao, et al.
Publicado: (2020)

SARS-CoV-2 and Human Immunodeficiency Virus: Pathogen Pincer Attack
por: Evans, Nicholas, et al.
Publicado: (2021)

Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone
por: Su, Shan, et al.
Publicado: (2022)

Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China
por: Liu, Qianyun, et al.
Publicado: (2021)

Analysis of proteins that interact with nucleocapsid protein of SARS-CoV using 15-mer phage-displayed library
por: Liu, ZhengXue, et al.
Publicado: (2007)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)

Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2
por: Lan, Jun, et al.
Publicado: (2022)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Recurrent SARS-CoV-2 mutations in immunodeficient patients
por: Wilkinson, S A J, et al.
Publicado: (2022)

SARS-CoV-2 replicon for high-throughput antiviral screening
por: Zhang, Qiu-Yan, et al.
Publicado: (2021)

The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1)
por: Henke, Wyatt, et al.
Publicado: (2022)

The Envelope Proteins from SARS-CoV-2 and SARS-CoV Potently Reduce the Infectivity of Human Immunodeficiency Virus type 1 (HIV-1)
por: Henke, Wyatt, et al.
Publicado: (2022)

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
por: Ma, Chengbao, et al.
Publicado: (2022)

B-Cell-Epitope-Based Fluorescent Quantum Dot Biosensors for SARS-CoV-2 Enable Highly Sensitive COVID-19 Antibody Detection
por: Zheng, Yucheng, et al.
Publicado: (2022)

Coronavirus in Continuous Flux: From SARS‐CoV to SARS‐CoV‐2
por: Dong, Yetian, et al.
Publicado: (2020)

Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency
por: Delavari, Samaneh, et al.
Publicado: (2020)

Antibody Response to SARS CoV-2 Immunization in Patients with Immunodeficiency
por: DiGiacomo, Daniel, et al.
Publicado: (2022)

SARS-CoV-2 reinfection or persistence among immunodeficient patients
por: Özdemir, Öner
Publicado: (2023)

Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice
por: Liu, Honghui, et al.
Publicado: (2023)

Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
por: Xiong, Rui, et al.
Publicado: (2020)

Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
por: Bai, Lei, et al.
Publicado: (2021)

Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
por: Xiong, Rui, et al.
Publicado: (2020)

Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2
por: Xiong, Rui, et al.
Publicado: (2020)

The challenge of emerging SARS-CoV-2 mutants to vaccine development
por: Li, Rong, et al.
Publicado: (2021)

Emerging SARS-CoV-2 variants of concern and potential intervention approaches
por: Khateeb, Jasmin, et al.
Publicado: (2021)

Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2
por: Zhang, Ya-Nan, et al.
Publicado: (2021)

Molecular Architecture of the SARS-CoV-2 Virus
por: Yao, Hangping, et al.
Publicado: (2020)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
por: Liu, Tong, et al.
Publicado: (2021)

A comprehensive survey of bat sarbecoviruses across China in relation to the origins of SARS-CoV and SARS-CoV-2
por: Wu, Zhiqiang, et al.
Publicado: (2022)

A Conversation Between Two Viruses: SARS-CoV and SARS-CoV-2 — Based on a True Story
por: Diamandis, Eleftherios P.
Publicado: (2020)

SARS-CoV-2 Nucleocapsid Protein Has DNA-Melting and Strand-Annealing Activities With Different Properties From SARS-CoV-2 Nsp13
por: Zhang, Bo, et al.
Publicado: (2022)

Cross-species recognition and molecular basis of SARS-CoV-2 and SARS-CoV binding to ACE2s of marine animals
por: Li, Shihua, et al.
Publicado: (2022)

Patterns of HIV and SARS‐CoV‐2 co‐infection in Wuhan, China
por: Guo, Wei, et al.
Publicado: (2020)

Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
por: Arroyo-Sánchez, Daniel, et al.
Publicado: (2021)

Immune Response to SARS-CoV-2 Infections in Children with Secondary Immunodeficiencies
por: Kuczborska, Karolina, et al.
Publicado: (2022)

Reply to “SARS-CoV-2 reinfection or persistence among immunodeficient patients”
por: Marcus-Mandelblit, Nufar, et al.
Publicado: (2023)

SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
por: Li, Yijia, et al.
Publicado: (2023)

Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020
por: Liu, Rui, et al.
Publicado: (2020)

SARS-CoV-2 infection in the mouse olfactory system
por: Ye, Qing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hb2uvrlm42lujtu6gt3idv9hce